Airiver Medical today announced the successful treatment of the first patient in a pivotal clinical trial of its drug-coated balloon (DCB). The first patient received treatment for chronic rhinosinusitis (CRS) in its RESTORE-2 U.S. pivotal clinical trial. It evaluates the Brooklyn Park, Minnesota-based company’s Airiver ESSpand sinus DCB. Dr. Andrew Gould treated the first patient […]
Drug-Device Combinations
Senseonics, Welldoc partner on next-gen Eversense 365 app development
Senseonics (NYSE:SENS) and Welldoc today announced a strategic partnership to develop a new custom mobile application for Eversense 365. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. The implant […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Beta Bionics real-world data shows 25% time in range improvement with iLet
Beta Bionics (Nasdaq:BBNX) said real-world data discussed last weekend highlighted the impact of its iLet Bionic Pancreas platform. The company said conversations with clinicians at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans covered improved outcomes and easier follow-up visits. The Irvine, California-based company said outcomes demonstrated how iLet supports diabetes care […]
CeQur closes $100M Series E to support mealtime insulin patch
CeQur announced today that it closed a $100 million Series E financing round to support its mealtime insulin delivery technology. Horw, Switzerland-based CeQur develops the Simplicity mealtime insulin patch pump system. The wearable, disposable bolus insulin delivery system was developed as, essentially, a wearable insulin pen. CeQur began a pilot commercial launch for the FDA-cleared […]
Sequel Med Tech chief medical officer explains why company is ‘excited about what’s ahead’
Sequel Med Tech has a habit of making waves at the American Diabetes Association’s annual Scientific Sessions event. In 2024, the Manchester, New Hampshire-based company was generating buzz following its entry into the automated insulin delivery market with twiist, its pump system, which had garnered FDA clearance in March of that year. At last year’s […]
Dexcom CEO Jake Leach talks Nutrisense acquisition, type 2 push, next-gen G8
Nearly halfway through 2026, the milestones are already stacking up for continuous glucose monitor (CGM) maker Dexcom (Nadsaq:DXCM). President and CEO Jake Leach took over the corner office in January. In the months that have followed, highlights include the unveiling of the next-generation G8 sensor system, the launch of the Flex sensor platform outside the […]
Terrestrial Bio data backs needle-free patch for GLP-1 delivery
Terrestrial Bio today shared new preclinical data demonstrating the translatability of its patch technology for delivering GLP-1 therapies. Boston-based Terrestrial (formerly Vaxess Technologies) shared findings at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Outcomes showed the translatability of the proprietary Tacterra MAP platform to deliver next-generation obesity therapies that involve co-delivery […]
Sequel Med Tech data supports twiist automated insulin delivery in type 2 diabetes
Sequel Med Tech today announced clinical findings supporting its twiist automated insulin delivery (AID) system in type 2 diabetes. twiist, which works with the twiist Loop algorithm, powered by Tidepool, directly measures the volume of insulin delivered with every microdose. The system offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system […]
Senseonics study supports Eversense 365 CGM with automated insulin delivery tech
Senseonics (NYSE:SENS) today announced real-world evidence supporting the performance of its Eversense 365 year-long CGM implant. Eversense 365 is a 365-day implantable continuous glucose monitor (CGM) that rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. Germantown, Maryland-based Senseonics said data […]
